Pfizer to raise prices on 41 drugs in 2019

Amy Baxter | | Health Exec | Policy & Regulations
Researchers found millions of heart failure patients who qualify for standard, guideline directed medical therapies, but did not receive it due to poor health literacy, limited access to care and medication costs.

Drug manufacturer Pfizer announced it would raise the prices of 41 drugs in January 2019, The Wall Street Journal reported. The move comes after the company committed to not raising prices in 2018 after coming under fire from President Trump. That commitment did not extend into 2019.

Most of the increases will be 5 percent, though one drug’s price will jump 9 percent, while three will only increase 3 percent, the WSJ reported. Most of the company’s portfolio of prescription drugs––90 percent––won’t be impacted by the price increases.

Rising drug prices have become a hot topic for the Trump administration, which has taken several steps to challenge the drug industry.

See the full story below:

Pfizer to Raise Prices on 41 Drugs in January

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

FDA issues Class I alert on Philips ventilators after 4 injuries
Trump selects Emmy-winning TV personality Dr. Oz to head CMS
FDA issues Class I recall of infusion pump batteries due to risk of burns
When life sciences met artificial intelligence
DEA, HHS extend telehealth controlled substance prescription rule
Public health contrarian RFK Jr. nominated to HHS secretary

Around the web

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

Cardiovascular Business
FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Design by Adaptive Theme
Trimed Popup
Trimed Popup